News • Stealthy survivors

Tracing the evolution of E. coli

Chemical engineers discover how some bacteria resist threats

The World Health Organization calls antibiotic resistance “one of the biggest threats to global health, food security, and development today.” Each year, about 2 million people in the United States become infected with antibiotic-resistant bacteria, according to the Centers for Disease Control. These infections are difficult to treat and increasingly deadly. In the face of this threat, scientists want to figure out exactly how bacteria evolve. A team from the University of Delaware and University of California, San Diego recently uncovered new insights about how E. coli bacteria mutate in response to a life-threatening challenge. Their results were published in Proceedings of the National Academy of Sciences (PNAS).

A bioreactor is used to encourage the growth and evolution of the bacteria...
A bioreactor is used to encourage the growth and evolution of the bacteria under investigation.
Credit: University of Delaware/ Evan Krape

A unique approach

“We wanted to study how cells recover from a major blow,” said co-author Maciek R. Antoniewicz, Centennial Professor of Chemical and Biomolecular Engineering at the University of Delaware. UD graduate engineering students Christopher Long and Jacqueline Gonzalez co-authored the paper with Antoniewicz. To do this, the team brought together two experimental methods that aren’t typically used in tandem: whole-genome sequencing and metabolic flux analysis. “One of the novelties of this paper is that we used two complementary approaches to elucidate how these cells evolved,” Antoniewicz said. “This is one of the first times both approaches were combined to see a link between genotype and phenotype.”

At UC-San Diego, Adam Feist, an associate project scientist in bioengineering, and Bernhard Palsson, the Galletti Professor of Bioengineering, modified and then evolved ten strains of E. coli bacteria. They knocked out the bacterial cells’ ability to utilize phosphoglucose isomerase, an enzyme that plays a critical role in the metabolism of glucose, a sugar. Robbing E. coli cells of the phosphoglucose isomerase enzyme is akin to starving them, stunting their growth by 80 percent. However, as these E. coli cells evolved and multiplied, they eventually recovered between 46 and 71 percent of their growth rate. The research team then used genomic analysis and flux analysis to figure out how the cells mutated and adapted to recover. Antoniewicz is a leading expert in flux analysis, so those experiments happened at the University of Delaware.  

Antoniewicz, Long, and Gonzalez found three mutations, in the genes sthA, pntAB, and crr, that helped the E. coli cells recover growth. These mutations helped the cells speed up metabolic steps that had been hampered by the absence of phosphoglucose isomerase. “It’s fascinating that you can get rid of one of the most important genes in glucose metabolism and the cell will recover,” Antoniewicz said. “This is evidence of the great flexibility of biological systems.” However, this adaptability is a blessing and a curse, as in the case of antibiotic-resistant bacteria. “Cells are flexible and nimble,” he said. “If you want to stop them from growing, using a single target may not be enough.” 

Next, the team is studying a new set of E. coli strains with different characteristics.


Source: University of Delaware

25.01.2018

Read all latest stories

Related articles

Photo

News • MTX in the mix

Researchers develop novel therapy for vancomycin-resistant infections

Researchers from the US, Singapore and Geneva have developed a novel combination therapy using an anticancer agent for treating vancomycin-resistant Enterococcus faecalis (VRE).

Photo

News • Infectious disease research

Hidden bacteria increases risk of antimicrobial resistant infection in hospital patients

Carriers of a specific bacteria have a 14% chance of developing an antibiotic resistant infection with 30 days of hospitalisation, according to new research from Amsterdam.

Photo

News • Breakthrough against C. diff

New Clostridioides difficile vaccine on the horizon

Researchers at the University of Exeter first identified a gene in the 'hospital bug' Clostridioides difficile responsible for producing a protein that aids in binding the bacteria to the gut of its…

Related products

Siemens Healthineers – Fast Track Real-time PCR assays

Infectious Disease

Siemens Healthineers – Fast Track Real-time PCR assays

Siemens Healthcare GmbH
MolGen – PurePrep 96

Extraction

MolGen – PurePrep 96

MolGen
Sarstedt – Low DNA Binding Micro Tubes

Research Use Only

Sarstedt – Low DNA Binding Micro Tubes

SARSTEDT AG & CO. KG
Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Mass Spectrometry

Shimadzu – CLAM-2030 CL (IVD)/ CLAM-2030 (RUO)

Shimadzu Europa GmbH
Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Mass Spectrometry

Shimadzu – LCMS-8060NX CL (IVD) / LCMS-8060 NX (RUO)

Shimadzu Europa GmbH
Subscribe to Newsletter